Multimodal "synergistic" treatment based on tumour immunological contexture for advanced non-driver non-small cell lung cancer: A myth or reality?

Eur J Cancer Care (Engl). 2020 Sep;29(5):e13291. doi: 10.1111/ecc.13291. Epub 2020 Jul 24.

Authors

Farkhad Manapov^{1

2

3}, Lukas Käsmann^{1

2

3}, Olarn Roengvoraphoj¹, Claus Belka^{1

2

3}, Chukwuka Eze¹

Affiliations

¹ Department of Radiation Oncology, University Hospital LMU Munich, Munich, Germany.
² Comprehensive Pneumology Center Munich (CPC-M), German Center for Lung Research (DZL), Munich, Germany.
³ German Cancer Consortium (DKTK), Munich, Germany.

PMID: 32705732
DOI: 10.1111/ecc.13291

No abstract available

MeSH terms

Carcinoma, Non-Small-Cell Lung* / therapy
Combined Modality Therapy
Humans
Lung Neoplasms* / therapy

Grants and funding

Open access funding enabled and organized by Projekt DEAL.